Ipsen Achieves Primary and Secondary Endpoints in DIRECTION Head-to-Head Dysport vs. Botox Phase IV Trial

Post-approval evidence generation for established biologics just gained a rigorous new benchmark: Ipsen's DIRECTION trial has delivered the first prospective, double-blind, head-to-head comparison of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA) in adults with upper limb spasticity, meeting both its primary and secondary endpoints. For regulatory affairs leads and QA directors managing labeling strategy or comparability packages for botulinum toxin products, the trial's design sets a reference point for what Phase IV comparative evidence can look like under controlled, instrument-guided conditions.

The Phase IV crossover trial enrolled 464 patients across 72 sites in the USA, France, and Canada (NCT04936542). On the primary safety endpoint, Dysport demonstrated non-inferiority to Botox with treatment-emergent adverse event rates of 20.3% versus 23.0%, respectively; the adjusted difference was −2.7% (80% CI: −6.2%, 0.9%). The secondary efficacy endpoint was also met: Dysport-treated patients achieved a longer duration of effect compared with Botox (14.2 vs. 13.8 weeks; adjusted difference favoring Dysport, 80% CI: 0.2, 5.9; p=0.17 against a pre-specified significance threshold of p=0.20). Consistency across most demographic and clinical subgroups strengthens the generalizability of the duration finding.

The trial's crossover design, in which each participant received one treatment cycle with each toxin under standardized, instrument-guided injection techniques, directly addresses the methodological criticism that has historically limited cross-product comparisons in the botulinum toxin class. That design discipline is relevant to manufacturers and regulatory teams: standardized administration protocols reduce confounding from injection variability, a factor that has complicated prior real-world comparisons and post-market surveillance interpretations.

Published data cited in the trial context indicate that over 80% of patients experience breakthrough symptoms between injection cycles and more than 70% report a need for longer-lasting treatment. The 0.4-week difference in duration of effect, while modest in absolute terms, was pre-specified and statistically evaluated within a framework designed to detect clinically meaningful differences in a chronic, cyclically dosed population. Results were presented as a late-breaking session at the ISPRM world congress in Vancouver on May 19, 2026.

The DIRECTION dataset now forms part of Dysport's post-approval evidence base, and its structured comparability methodology may inform how future Phase IV programs for biologic products in the same class approach head-to-head design, endpoint selection, and confidence interval pre-specification under ICH and FDA post-market requirements.

Source: Ipsen via GlobeNewswire, May 19, 2026. Data presented at the ISPRM World Congress, Vancouver, late-breaking session, May 19, 2026.